
## Peter Krajci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1557401/publications.pdf Version: 2024-02-01



DETED KDAICI

#	Article	IF	CITATIONS
1	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. JAMA Psychiatry, 2017, 74, 1197.	11.0	200
2	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. JAMA Psychiatry, 2019, 76, 127.	11.0	44
3	Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. Journal of Public Health, 2016, 38, e368-e374.	1.8	28
4	Effectiveness, safety and feasibility of extendedâ€release naltrexone for opioid dependence: a 9â€month followâ€up to a 3â€month randomized trial. Addiction, 2018, 113, 1840-1849.	3.3	20
5	No increased pain among opioidâ€dependent individuals treated with extendedâ€release naltrexone or buprenorphineâ€naloxone: A 3â€month randomized study and 9â€month openâ€treatment followâ€up study. American Journal on Addictions, 2019, 28, 77-85.	1.4	16
6	Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. Clinical Therapeutics, 2015, 37, 1594-1599.	2.5	13
7	Buprenorphine dosing choices in specific populations: review of expert opinion. Expert Opinion on Pharmacotherapy, 2016, 17, 1727-1731.	1.8	13
8	The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting. European Addiction Research, 2018, 24, 286-292.	2.4	8
9	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. European Addiction Research, 2019, 25, 303-309.	2.4	7
10	Adapting treatment length to opioidâ€dependent individuals' needs and preferences: a 2â€year followâ€up to a 1â€year study of extendedâ€release naltrexone. Addiction, 2021, 116, 2084.	) 3.3	5
11	Concentrations of psychoactive substances in blood samples from nonâ€fatal and fatal opioid overdoses. British Journal of Clinical Pharmacology, 2022, , .	2.4	4